FENC

13.0902.68%
JS

Jeffrey S. Hackman

CEO & Director

Mr. Jeffrey S. Hackman, also known as Jeff, is CEO & Director of Fennec Pharmaceuticals Inc. from August 16, 2024. He served as Chairman, President and Chief Executive Officer of Comera Life Sciences Holdings, Inc. from May 20, 2022 until January 31, 2024. He served as President, Chief Executive Officer & Chairman at Comera Life Sciences, Inc. from September 1, 2021 to January 31, 2024. Mr. Hackman served as President of United States' operations at EUSA Pharma, Inc. since December 5, 2018 until 2021. Mr. Hackman served as the Chief Operating Officer and Executive Vice President of Novelion Therapeutics Inc. since November 1, 2017 until November 19, 2018 and served as its Interim Chief Executive Officer from July 03, 2018 until November 19, 2018. From 2017 to 2018, Mr. Hackman filled several roles at Aegerion Pharmaceuticals Inc. He has a strong track record of building and leading commercial organizations and delivering business growth. He was Senior Vice President and Head of US Internal Medicine / Oncology at Shire Inc. from 2016 to 2017, following a period leading the company's US oncology franchise. Mr. Hackman was Vice President and Region Head for North America at Baxalta US, following several years leading US commercial operations for Sigma Tau. He also held senior roles in a number of other pharmaceutical companies. Mr. Hackman served as Vice President of Commercial Operations at Sigma Tau Pharmaceuticals, Inc. from October 29, 2012 to November 1, 2017 and served as its Chief Operating Officer. He was Senior Vice President of commercial operations, Chief Operating Officer and board member at Sigma Tau Health Sciences USA. He served as Senior Vice President of Commercial & Business Development at Bionor Immuno AS. He has commercial and business development experience in different pharmaceutical and biotechnology companies such as Aventis Pasteur and Medimmune in the United States. He served as the Chief Executive Officer of the U.S. office and Global Senior Vice President of Commercial Operations at Intercell AG, where he managed the group global marketing and sales function, focusing on the successful launch of the Company's first licensed product. Mr. Hackman served as Vice President Marketing and Sales of Emergent BioSolutions Inc. He served as Vice President of Marketing for MedImmune, Inc. He held a number of marketing positions at Aventis Pasteur, Inc. since 1994, including director of marketing with responsibility for product management, market research, analytical services and marketing communications. Prior to Aventis, Mr. Hackman spent eight years with Lederle Laboratories. He completed his bachelor of arts degree at Lycoming College. Mr. Hackman holds an MBA in Marketing from University of Phoenix, AZ.

Positions